EFPIA welcomes EMA's future-proofing of processes

2 July 2019

The European Medicines Agency (EMA) is seeking to ensure that its regulatory processes keep pace with the innovation and change going on in the drug development industry.

With this in mind, the agency is consulting on its Regulatory Science Strategy (RSS) going forward to 2025, and its strategic reflection document sets out five broad goals and core recommendations.

"EMA’s RSS 2025 will be a key enabler for bringing the promising next wave of medical innovation to patients"The EMA’s first goal is to drive forward the integration of science and technology in medicines development, while its second is to encourage collaborative evidence generation and improve the scientific quality of evaluations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK